MDT interaction in two comparable NSCLC stage IIIA patients

Torsten Gerriet Blum (Berlin, Germany)

Source: International Congress 2015 – Lung cancer: the need for a multidisciplinary approach - an interactive session

WebcastSlide presentationMultimedia files

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Torsten Gerriet Blum (Berlin, Germany). MDT interaction in two comparable NSCLC stage IIIA patients. International Congress 2015 – Lung cancer: the need for a multidisciplinary approach - an interactive session

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
NSCLC stage IV
Source: European Multidisciplinary Conference in Thoracic Oncology 2009
Year: 2009

Validity of predictive estimate by physicians of the survival of patients with recently diagnosed stages IIIB and IV non-small cells lung cancer (NSCLC)
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007


Stage IIIB and stage IV non-small cell lung cancers; responses to treatment and survival durations
Source: Eur Respir J 2004; 24: Suppl. 48, 302s
Year: 2004

Analysis of prognostic factors in patients with stage IIIB, IV non-small cell lung cancer
Source: Annual Congress 2010 - Staging of lung cancer
Year: 2010


Disease relapse in surgically and conservatively treated patients with stage I-II of non-small cell lung cancer
Source: Annual Congress 2010 - Thoracic malignancies: interesting case studies and series
Year: 2010

Treatment tolerance and survival in elderly patients with stage IV non-small cell lung cancer (NSCLC)
Source: International Congress 2019 – Symptoms, risks, complications and palliative care in thoracic oncology
Year: 2019


A new TNM classification is better than ISS at predicting survival in stage III unresectable non-small cell lung cancer (NSCLC). A study by the European lung cancer working party (ELCWP)
Source: Eur Respir J 2003; 22: Suppl. 45, 163s
Year: 2003

A single centre review of palliative chemotherapy in newly diagnosed stage IIIb and IV lung cancer patients with good performance status
Source: Annual Congress 2013 –Systemic therapy of lung cancer and quality of life
Year: 2013


Docetaxel in combination with carboplatin in the treatment of Stage IIIb and IV non-small cell lung cancer patients. A Phase II study
Source: Eur Respir J 2005; 26: Suppl. 49, 77s
Year: 2005

Selective adjuvant chemotherapy according to in-vitro chemoresistance test: Long term follow up of patients with resectable non-small cell lung cancer (NSCLC) stage IIIA
Source: Annual Congress 2010 - Treatment of lung cancer
Year: 2010

Resectability after two different chemotherapy regimens: results of the first step of a phase II randomised trial in initially resectable stage I – IIIa nonsmall cell lung cancer conducted by the European lung cancer working party
Source: Eur Respir J 2003; 22: Suppl. 45, 162s
Year: 2003

Management of locally advanced nonsmall cell lung cancer
Source: Eur Respir Mon; 2009: 44: 260–270
Year: 2009

Stage IIIA-N2 non-small cell lung cancer (NSCLC): comparison of prognostic factors in 257 patients treated with surgery (S) versus induction chemotherapy plus surgery (IC+S)
Source: Eur Respir J 2002; 20: Suppl. 38, 597s
Year: 2002

Postoperative adjuvant treatment in stage III NSCLC
Source: Eur Respir J 2007; 30: Suppl. 51, 434s
Year: 2007

Stage IIIA/B NSCLC: long-term results of induction chemotherapy and surgery
Source: ISSN=ISSN 1810-6838, ISBN=, page=279
Year: 2008

A multicenter phase II study of docetaxel (D) weekly in advanced non-small cell lung cancer (NSCLC) in elderly and/or poor performance status (PS) patients (pts): preliminary results of the 0202 GFPC study
Source: Annual Congress 2005 - Chemotherapy and palliative care
Year: 2005


Survival of patients operated for stage I non-small-cell lung cancer
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008